Local News

• The CYPHER(R) Stent outperforms the Taxus(R) Stent in people with diabetes  In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with lower rates of in-segment restenosis, target lesion revascularization and major adverse events at nine months according to clinical data.
  Johnson & Johnson August 28, 2008  
• Monsanto and Evogene collaborate on yield and stress research  Monsanto Company and Evogene have entered into a five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization.
  Monsanto Company August 28, 2008  
• Amgen alters anemia drug discounts  Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety.
  The New York Times August 27, 2008  Andrew Pollack
• CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent receives CE Mark approval  Cordis Corporation announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack.
  Johnson & Johnson August 27, 2008  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc. August 26, 2008  
• Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program  Bristol-Myers Squibb Company and Pfizer provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
  Pfizer Inc. August 26, 2008  
• VYVANSE(R) now available in U.S. pharmacies nationwide in six dosage strengths  Shire Limited has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
  Shire August 26, 2008  
• Stanford to limit drug maker financing  Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school.
  The New York Times August 25, 2008  Gardiner Harris
• Genzyme and Medicines for Malaria Venture announce new collaboration with Advinus  Genzyme and Medicines for Malaria Venture announced a new collaboration with India’s Advinus Therapeutics. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria.
  Genzyme Corporation August 25, 2008  
• Patients taking Cymbalta(R) experienced reduced chronic low back pain in new study  Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.
  Eli Lilly and Company August 25, 2008  

   (next 10 articles)